Zihipp Limited, a UK-based biopharmaceutical company focused on the development of peptide hormones for the treatment of diabetes and obesity, announces it has signed an exclusive license and option agreements with Imperial College London.

The exclusive license includes the pre-clinical and clinical data packages for two oxyntomodulin and PYY analogue programmes which have successfully completed phase I clinical trials, along with several GLP-1, PYY and oxyntomodulin discovery programmes.

read more